Alfa Cytology - Cancer Drug R&D Services

Cervical Cancer

Inquiry

Cervical cancer is a malignancy closely associated with HPV infection and with high risk of local invasion and pelvic dissemination, and is one of the most common malignancies among women worldwide. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for cervical cancer animal model development, efficacy evaluation, cervical orthotopic model validation, pelvic invasion and metastasis evaluation, radiotherapy combination studies, tumor immunology testing, target expression validation, pathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, HPV status, histological background, target type, immune system requirements, local treatment scenario, administration route, and R&D stages. We also provide zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.

Introduction to Cervical Cancer

Cervical cancer is a malignant tumor originating from cervical epithelium and is closely associated with persistent infection by high-risk HPV (especially HPV16 and HPV18), and is one of the most common malignancies among women worldwide. Cervical cancer is characterized by clear HPV stratification, strong local invasion, and high pelvic dissemination risk. Clinically, cervical cancer is commonly managed based on stage, HPV status, and histological type. Early cervical cancer can be treated with surgery or radiotherapy; locally advanced cervical cancer is mainly treated with concurrent chemoradiotherapy; relapsed and metastatic cervical cancer relies more on immune checkpoint inhibitors, ADCs, bispecifics, and cell therapy. HPV E6/E7, p16, tissue factor, and PD-L1 are important targets in current drug development. Common metastatic routes in cervical cancer include pelvic lymph node metastasis, lung metastasis, and peritoneal dissemination. Among these, pelvic lymph node metastasis and local relapse are high-priority scenarios in translational research. The cervical cancer immune microenvironment, tumor-infiltrating lymphocytes, PD-L1 expression, and cytokine networks play important roles in treatment response and resistance.

The progression of cervical cancer is generally divided into four stages.Fig.1 The four stages of cervical cancer.

Our Services

Alfa Cytology has established a comprehensive solution platform for cervical cancer animal experimental research, built around HPV16/HPV18 stratification, local cervical orthotopic microenvironment, pelvic invasion and lymph node metastasis, lung/peritoneal distant dissemination, radiotherapy combination, ADC/immunotherapy, HPV antigen therapy, and relapse/MRD scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full cervical cancer research workflow.

Preclinical Efficacy Studies

Cervical cancer drug development requires model selection based on HPV status, histological background, local orthotopic scenario, target expression, immune system, and administration route. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for cytotoxic agents, targeted agents, ADCs, bispecifics, TCEs, CAR-T/NK, PD-1/PD-L1, CTLA-4, therapeutic vaccines, radiotherapy combination, local delivery, and anti-relapse programs.

In Vitro and In Vivo Layered Validation

Animal studies can evaluate whether a candidate inhibits tumor growth, orthotopic invasion, metastasis, or relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, cervical orthotopic colonization, pelvic invasion, metastatic invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, HPV E6/E7, target expression, ADC internalization, radiosensitivity, and immune killing.

Clinical Relevance Studies

When programs advance to local invasion, radiotherapy combination, local delivery, HPV antigen immunity, metastasis, relapse, or MRD stages, Alfa Cytology can further provide orthotopic models, metastasis models, syngeneic immunocompetent models, humanized immune models, or relapse models to help clients generate evidence more aligned with clinical scenarios.

Cervical Cancer Mechanism Research

For cervical cancer studies, experimental design typically needs to address HPV background, local microenvironment, pelvic invasion, immune response, and radiotherapy response simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering HPV E6/E7, p16, DNA damage repair, tumor immunity, local delivery, pelvic metastasis, and relapse mechanisms.

Candidate Screening

Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, and target evaluations using HPV status-matched subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.

Molecular Mechanism Studies

Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, HPV E6/E7 testing, tissue factor expression, immune profiling, DNA damage markers, PK/PD, and local tissue drug distribution testing.

For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation,translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:

Supported R&D Programs

R&D Project Cell Lines Host System Preferred Model Key Endpoints
Early efficacy screening and dose exploration SiHa, HeLa, CaSki, C-33 A BALB/c nude, NOD-SCID, NSG Subcutaneous CDX TGI, RTV, terminal tumor weight, body weight, Ki67, apoptosis, PK/PD.
HPV16-related drug and antigen programs SiHa, CaSki Immunodeficient mice or TC-1 + C57BL/6 SiHa/CaSki CDX, orthotopic or TC-1 immune model for confirmation HPV E6/E7, p16, tumor burden, CD8 infiltration, cytokines, survival.
HPV18-related mechanism research HeLa, HeLa-luc Immunodeficient mice HeLa CDX, orthotopic validation when needed TGI, RTV, HPV18-related markers, Ki67, apoptosis, target pathway.
HPV-negative / p53-abnormal background C-33 A Immunodeficient mice C-33 A CDX or control model TGI, cell cycle, p53 pathway, apoptosis, DNA damage markers.
Cervical local invasion and pelvic extension SiHa-luc, CaSki-luc, HeLa-luc Immunodeficient mice Cervical orthotopic model BLI/IVIS, orthotopic burden, parametrial invasion, pelvic invasion, local pathology, survival.
Local delivery / local tissue distribution SiHa-luc, CaSki-luc, HeLa-luc Immunodeficient mice Cervical orthotopic model or mucosa-related orthotopic model Local tissue drug concentration, orthotopic burden, lesion penetration, local irritation, pathology.
Radiosensitization / concurrent chemoradiotherapy SiHa-luc, CaSki-luc, HeLa-luc, TC-1 orthotopic model Immunodeficient mice; C57BL/6 immunocompetent mice Cervical orthotopic model, with relapse observation when needed Tumor burden, DNA damage, apoptosis, local residual disease, time to relapse, survival.
Lung metastasis and distant dissemination SiHa-luc, CaSki-luc, HeLa-luc and derivatives Immunodeficient mice Tail vein experimental lung metastasis or orthotopic spontaneous metastasis BLI/IVIS, lung nodule count, lung weight, histopathology, survival.
Lymph node metastasis and pelvic dissemination SiHa-luc, CaSki-luc Immunodeficient mice Cervical orthotopic model with extended observation Pelvic lymph nodes, local invasion extent, pelvic pathology, IVIS, survival.
HPV antigen immunity / therapeutic vaccines TC-1 / TC-1-luc C57BL/6 TC-1 syngeneic subcutaneous model for startup, TC-1 orthotopic/mucosal model for confirmation Tumor volume, CD8/Treg, IFN-γ, E6/E7-specific responses, survival.
TCE / CAR-T/NK / Human immune-dependent therapies SiHa, CaSki, HeLa, C-33 A huPBMC or huHSC humanized mice Humanized immune model hCD45, hCD3, hCD8, hNK, tumor burden, cytokines, xGvHD/CRS risk.
ADC / Tissue factor (TF) targeted modalities SiHa, CaSki, HeLa or TF-positive lines Immunodeficient mice Target-positive CDX for startup, orthotopic model for confirmation TGI, TF expression, ADC tissue distribution, apoptosis, necrosis, PK/PD.
Post-surgical recurrence / MRD clearance SiHa-luc, CaSki-luc, TC-1-luc Immunodeficient or immunocompetent mice Orthotopic model with local treatment followed by relapse observation IVIS recurrence, local recurrence rate, pelvic metastasis, survival, residual disease markers.

Comprehensive Test and Data Analysis Platform

For cervical cancer programs focused on HPV status, local invasion, and radiotherapy combination evaluation, we configure TGI, RTV, terminal tumor weight, BLI, survival, orthotopic cervical burden, parametrial invasion, pelvic lymph nodes, lung nodules, HPV E6/E7, p16, tissue factor, γH2AX, and local tissue distribution, supporting local lesion control, pelvic dissemination, and HPV-related mechanism evaluation.

Multimodal In Vivo Imaging

  • IVIS Spectrum photon bioluminescence quantification for orthotopic cervical tumors and pelvic dissemination tracking
  • 7.0T small-animal high-field MRI for pelvic lesion and local invasion scanning
  • micro-CT 3D reconstruction for pelvic and distant metastatic assessment

Pathology and IHC/IF Staining

  • HPV E6/E7 / p16 / tissue factor target assessment
  • γH2AX / Ki67 / Cleaved-Caspase 3 DNA damage and apoptosis index
  • mIF multiplex immunofluorescence for in situ target and cervical TME quantification

TME Microenvironment and Immune Profiling

  • Cervical tumor TILs (CD4+ / CD8+ / Treg) infiltration analysis
  • Post-radiotherapy immune infiltration and immune checkpoint changes
  • Cytokine storm (IFN-γ / IL-6) CBA suspension array

Access Our Cervical Cancer Model Library

Cervical Cancer Cell Line Panel

Alfa Cytology's cervical cancer cell line panel covers HPV16/HPV18 stratification, cervical orthotopic microenvironment, local invasion and pelvic dissemination, radiotherapy combination, and immuno-oncology, enabling cell line selection and matching based on HPV status, local invasion capacity, target expression, and immune system requirements.

HPV16-Related Cell Lines

  • SiHa: classic HPV16-positive cervical squamous cell carcinoma cell line, widely used in vitro and in vivo, suitable for subcutaneous efficacy, cervical orthotopic, local invasion, radiotherapy combination, HPV E6/E7-related mechanisms, and partial ADC programs.
  • CaSki: also an HPV16-related model, suitable for HPV-driven mechanisms, local invasion, antigen expression stability, ADC, or membrane antigen-related strategy research.

HPV18-Related Cell Lines

  • HeLa: the most classic HPV18-related cervical cancer cell line, with high tooling degree, rich literature foundation, and stable tumor formation.
  • HeLa has a relatively special biological background; it is suitable for early efficacy and mechanism research, but should not be the sole basis for local invasion, pelvic metastasis, or clinical heterogeneity conclusions.

HPV-Negative or Atypical Background Cell Lines

  • C-33 A: a commonly used HPV-negative cervical cancer cell line, suitable for HPV-independent mechanisms, p53 abnormalities, DNA damage repair, resistance, and comparative research with HPV-positive models.
  • C-33 A has limited representativeness for mainstream HPV-dependent cervical cancer and is more suitable as a control platform or atypical mechanism research model.

Immuno-Oncology and HPV Antigen Models-Related Cell Lines

  • TC-1: an HPV16 E6/E7-related syngeneic model, typically used in C57BL/6 immunocompetent mice, suitable for therapeutic vaccines, T cell immunity, immune checkpoint, STING, cytokines, radiotherapy combination, and antigen-specific immune research.
  • TC-1 is a murine model and cannot fully substitute for human tumor target expression in human cervical cancer CDX, nor is it suitable for directly evaluating human ADCs or human target antibody drugs.

Drug Target-Related Cell Lines

  • Tisotumab vedotin-related or tissue factor-targeted programs should confirm tissue factor expression before modeling and re-verify target retention after tumor formation and at the endpoint stage.
  • Therapeutic vaccines, TCR-T, TCE, or HPV antigen-related immune programs should prioritize HPV16-related models or TC-1 models.
  • Cisplatin, radiosensitization, PARP/DNA damage response, and p53-related mechanism programs can select SiHa, HeLa, CaSki, or C-33 A based on HPV status and p53 background.

Cervical Cancer Animal Model Panel

Alfa Cytology provides end-to-end cervical cancer animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across HPV16/HPV18 stratification, local cervical orthotopic microenvironment, pelvic invasion and lymph node metastasis, lung/peritoneal distant dissemination, radiotherapy combination, ADC/immunotherapy, HPV antigen therapy, and relapse/MRD research. Each model can be customized to match your program's HPV status, histological background, target type, immune system requirements, local treatment scenario, administration route, and R&D stage, from early screening to clinical relevance validation.

Subcutaneous Xenograft Model (CDX)

Subcutaneous CDX models typically involve inoculating human cervical cancer cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume. Commonly used hosts include BALB/c nude, NOD-SCID, and NSG mice. Commonly used cell lines include SiHa, HeLa, CaSki, and C-33 A.

Model characteristics
SiHa subcutaneous CDX is suitable for HPV16-related programs, small molecules, cytotoxic agents, ADCs, radiotherapy sensitization, and combination regimen early efficacy screening. HeLa subcutaneous CDX is suitable for HPV18-related mechanism research, classical cytotoxic agents, molecular targeted agents, and early efficacy validation. CaSki subcutaneous CDX is suitable for HPV16-related targets, ADCs, local invasion early assessment, and antigen expression stability validation. C-33 A subcutaneous CDX is suitable for HPV-negative background, p53 abnormalities, DNA damage repair, resistance, and HPV-dependent/independent mechanism control research. This model has high standardization, suitable for early screening and PK/PD research; its limitations are the lack of cervical local epithelium, stroma, matrix invasion, pelvic anatomical relationships, and local immune environment.

Modeling and dosing timelines
Subcutaneous CDX typically reaches enrollment volume within 1–3 weeks, with randomization commonly performed at tumor volumes of approximately 80–150 mm3. The conventional treatment period is 2–4 weeks. For resistance, withdrawal rechallenge, long-term exposure, or sustained-release formulations, this can be extended to 4–8 weeks. Small molecules can be dosed daily or every other day; cytotoxic agents are often dosed weekly or cyclically; ADCs, antibodies, and long-acting formulations can be dosed weekly or every 2–3 weeks.

Detection endpoints

  • Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival
  • HPV and mechanism layer: p16, HPV E6/E7, Ki67, cleaved caspase-3, TUNEL, γH2AX, p53 pathway, cell cycle markers, and target expression
  • ADC and target layer: Tissue factor, membrane antigen expression, ADC tissue distribution, apoptosis/necrosis, bystander effect-related markers, and PK/PD
  • Safety layer: Body weight, complete blood count, liver and kidney function, major organ pathology, and dosing tolerance

Recommended positive controls
Cisplatin at 2–5 mg/kg IP or IV, once weekly or at intervals; carboplatin as a platinum alternative reference; paclitaxel at 10–20 mg/kg IP or IV, once weekly for 2–4 consecutive weeks. Bevacizumab or anti-VEGF-related agents as anti-angiogenesis direction references. Tisotumab vedotin as a clinical mapping reference for tissue factor-targeted ADC direction. Cisplatin concurrent radiotherapy as a basic reference framework for radiotherapy sensitization.

Cervical Orthotopic Model

Cervical orthotopic models typically involve inoculating cell suspensions or small tumor fragments into the cervix or adjacent anatomical sites, with SiHa-luc, CaSki-luc, or HeLa-luc selectable based on program. For dynamic observation, luc-labeled cells are recommended with IVIS longitudinal monitoring.

Model characteristics
SiHa orthotopic models are suitable for HPV16-related local invasion, parametrial invasion, pelvic extension, local delivery, radiotherapy combination, and relapse observation. CaSki orthotopic models are suitable for HPV16-related local invasion, antigen expression stability, local delivery, ADC, and bispecific early extrapolation. HeLa orthotopic models are suitable for HPV18-related local lesions, drug distribution, and mechanism research. This model has complex procedures, significant inter-batch variability, and low throughput, and is not suitable as a first-round rapid ranking platform for multiple candidates, but is suitable for local invasion, orthotopic efficacy, radiotherapy combination, local delivery, pelvic extension, relapse, and local microenvironment research.

Modeling and dosing timelines
Cervical orthotopic models typically require 1–3 weeks to form monitorable burden, depending on cell line, inoculation site, inoculation amount, and local fixation method. BLI/IVIS can be used for enrollment and follow-up. The conventional treatment period is 3–6 weeks. If radiotherapy, local resection, relapse, or MRD observation is involved, this can be extended to 6–10 weeks or longer. Treatment can begin after orthotopic tumor burden confirmation.

Detection endpoints

  • Orthotopic tumor burden layer: BLI/IVIS, orthotopic tumor size, local pathology, parametrial invasion, pelvic extension, and survival
  • Local invasion layer: Matrix invasion, local vascular invasion, lymphatic vessel invasion, pelvic lymph nodes, and cervical tissue structure destruction
  • Radiotherapy and DNA damage layer: γH2AX, cleaved caspase-3, TUNEL, Ki67, necrosis area, residual lesions, and time to relapse
  • Local delivery layer: Local tissue drug concentration, lesion penetration, mucosal/stromal distribution, local irritation, and tissue safety

Recommended positive controls
Cisplatin as a concurrent radiotherapy basic reference at 2–5 mg/kg at intervals. Cisplatin, carboplatin, paclitaxel, and bevacizumab-related strategies can be set based on program scenario. Tissue factor-targeted ADC programs can set tisotumab vedotin-related references. If TC-1 orthotopic or mucosa-related models are used, PD-1/PD-L1, CTLA-4, STING, or therapeutic vaccine-related references can be set.

Lung Metastasis Model

Lung metastasis models can use SiHa, CaSki, HeLa, or their luc derivatives, established via tail vein injection for experimental lung colonization models; if closer to the natural clinical process is desired, spontaneous lung metastasis can be observed by extending observation in cervical orthotopic models.

Model characteristics
Suitable for anti-metastasis agents, ADCs, combination regimens, post-circulation lung colonization, and distant organ activity evaluation. Tail vein models are more biased toward lung colonization and do not fully represent local invasion, lymphatic dissemination, and the complete natural metastasis process. Spontaneous metastasis models are closer to the clinical process but have longer cycles and greater variability.

Detection endpoints
BLI/IVIS, lung nodule count, lung weight, lung tissue HE, metastatic area, Ki67, apoptosis, EMT markers, and survival.

Recommended positive controls
Cisplatin, carboplatin, paclitaxel, and bevacizumab can be set as systemic therapy references based on research objectives. Tissue factor-targeted ADC programs can set tisotumab vedotin-related references.

Lymph Node Metastasis and Pelvic Dissemination Model

Lymph node metastasis and pelvic dissemination typically form based on SiHa-luc or CaSki-luc cervical orthotopic models. Time-series tracking can observe local invasion, pelvic lymph nodes, and regional extension.

Model characteristics
Suitable for local therapy, radiotherapy combination, peri-treatment intervention, regional control, and relapse/metastasis inhibition research. This model depends on orthotopic tumor formation and time window, and is not suitable for highest-throughput early screening. Local burden, regional metastasis, and endpoint sampling standards need to be strictly defined.

Detection endpoints
Pelvic lymph node size, pathological positivity rate, local invasion extent, pelvic pathology, IVIS, survival, lymphatic vessel markers, and local immune infiltration.

Recommended positive controls
Cisplatin, carboplatin, or paclitaxel can serve as systemic therapy references. If immunocompetent models are used, PD-1/PD-L1, CTLA-4, or radiotherapy combination references can be set.

Peritoneal or Organ Dissemination Model

Peritoneal or organ dissemination models can use HeLa, SiHa, or their luc derivatives, established via intraperitoneal injection, local organ inoculation, or orthotopic progression observation.

Model characteristics
Suitable for advanced dissemination, local implantation, abdominopelvic regional therapy, and local exposure strategy validation. Peritoneal or organ dissemination models have high standardization requirements and are suitable for specific advanced scenarios, not as a routine early screening platform.

Detection endpoints
Peritoneal tumor burden, organ nodules, ascites, survival, tissue pathology, BLI/IVIS, and local drug distribution.

Recommended positive controls
Cisplatin, carboplatin, paclitaxel, and bevacizumab can be set as systemic therapy references based on research objectives. Tissue factor-targeted ADC programs can set tisotumab vedotin-related references.

TC-1 Syngeneic Subcutaneous Model

TC-1 syngeneic subcutaneous models are typically established in C57BL/6 mice using HPV16 E6/E7-related murine cells subcutaneously. This model is suitable for immunotherapy, therapeutic vaccines, T cell responses, cytokines, and radiotherapy combination early screening.

Model characteristics
Suitable for HPV antigen therapy, immune checkpoint, radiotherapy combination, cytokines, and local immune microenvironment research. TC-1 is a murine model and cannot fully replace human target expression in human cervical cancer cell lines.

Modeling and dosing timelines
Enrollment occurs when tumor volume reaches approximately 50–100 mm3, with a treatment period of mostly 10–21 days. Immunotherapy programs should set sampling times based on the immune activation window.

Detection endpoints
Tumor volume, TGI, body weight, survival, CD8, Treg, myeloid cell profile, IFN-γ, Granzyme B, E6/E7-specific T cell responses, and IHC/IF.

Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks. HPV16 E6/E7 peptide, protein, DNA, RNA, or vector vaccines can serve as therapeutic vaccine references.

TC-1 Orthotopic or Mucosa-Related Model

TC-1-luc orthotopic or mucosa-related models can be established in C57BL/6 background, suitable for HPV antigen immunity, local radiotherapy combination, mucosal immunity, tumor microenvironment remodeling, and regional relapse research.

Model characteristics
Suitable for HPV antigen immunotherapy, immune combination, and radiotherapy combination research. This model retains an intact immune system, suitable for local immune microenvironment and regional metastasis research. Its limitation is the murine model nature, which cannot directly replace human target drug validation.

Detection endpoints
Orthotopic tumor burden, BLI/IVIS, survival, CD8/Treg, myeloid cell infiltration, IFN-γ, TNF-α, memory T cells, local tissue pathology, and metastatic burden.

Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks. Radiotherapy combination programs can set local irradiation combined with PD-1/PD-L1, vaccine, STING, or cytokine strategies.

huPBMC Model

The huPBMC model establishes a short-term human immune effector environment by infusing human peripheral blood mononuclear cells into immunodeficient mice, combined with human cervical cancer cell lines. SiHa, CaSki, HeLa, or C-33 A can be selected.

Model characteristics
Suitable for TCE, CAR-T/NK, human cytokines, immune checkpoint combination, and ADC or bispecific programs highly dependent on human immune effects. This model has long cycles, high cost, significant donor variability, and carries xGvHD or cytokine release risk.

Detection endpoints
hCD45, hCD3, hCD4, hCD8, hNK, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, CRS, and xGvHD risk markers.

Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanism references. TCE, CAR-T, or CAR-NK programs should include target-positive, low/negative, effector cell, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107 cells/mouse.

huHSC Model

The huHSC model reconstructs a longer-term human immune system via human hematopoietic stem cells, suitable for longer-cycle immunotherapy, resistance, relapse, and complex combination strategy validation.

Model characteristics
Suitable for long-cycle human immunotherapy, TCE, CAR-T/NK, bispecifics, immune resistance, and complex TME mechanism validation. This model has long cycles, high cost, significant donor variability, and carries xGvHD or cytokine release risk.

Detection endpoints
Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology.

Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanism references. TCE, CAR-T, or CAR-NK programs should include target-positive, low/negative, effector cell, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107cells/mouse.

Radiotherapy Combination, Postoperative Relapse, and Minimal Residual Disease Model

Radiotherapy combination models are typically based on SiHa-luc, CaSki-luc, HeLa-luc, or TC-1 orthotopic models. First, monitorable local lesions are formed, followed by local irradiation, concurrent chemotherapy, immune combination, or radiotherapy sensitization intervention. Relapse and MRD models typically involve local therapy, debulking, radiotherapy, or drug intervention after orthotopic tumor formation, followed by continuous tracking of local residual disease, IVIS relapse, pelvic metastasis, and survival.

Model characteristics
Suitable for radiotherapy sensitization, concurrent chemoradiotherapy, immune-radiotherapy combination, local delivery, postoperative relapse, pelvic relapse, and MRD clearance research. Radiotherapy combination and relapse models have high requirements for orthotopic lesion stability, radiotherapy localization, local treatment timing, and long-term follow-up, and are not suitable as a first-round high-throughput screening model.

Modeling and dosing timelines
First establish orthotopic tumor burden and confirm enrollment by IVIS or local lesion markers. Local radiotherapy, concurrent cisplatin, immunotherapy, ADC, or local delivery is set according to program, with a treatment period of typically 1–4 weeks. After treatment, observation continues for 2–6 weeks or longer, recording IVIS relapse, local relapse rate, pelvic metastasis, survival, and residual lesion markers.

Detection endpoints

  • Radiotherapy response layer: Tumor burden, γH2AX, cleaved caspase-3, TUNEL, Ki67, necrosis, residual lesions, and survival
  • Relapse layer: IVIS relapse time, local relapse rate, residual tumor burden, pelvic lymph nodes, lung metastasis, and survival
  • Immune combination layer: CD8, Treg, MDSC, macrophages, PD-L1, IFN-γ, Granzyme B, memory T cells, and cytokines
  • Safety layer: Body weight, local tissue injury, mucosal reaction, complete blood count, liver and kidney function, and major organ pathology

Recommended positive controls
Cisplatin concurrent radiotherapy as a radiotherapy combination basic reference. PD-1/PD-L1, CTLA-4, or cadonilimab-class dual immune checkpoint strategies as immune combination clinical mapping references. Tissue factor-targeted ADC direction can set tisotumab vedotin-related references.

How to Select the Right Model for Your Program?

By Development Stage

By Drug Type

By Research Objective

By Route of Administration

By Development Pathway

  • Early efficacy screening: For early candidate screening, dose exploration, or PK/PD, prioritize subcutaneous CDX. SiHa, HeLa, CaSki, and C-33 A can be selected based on HPV status, target, and mechanism.
  • Local invasion and organ scenario validation: If subcutaneous models show a signal and the program involves local cervical microenvironment, parametrial invasion, pelvic extension, local delivery, or radiotherapy combination, escalate to cervical orthotopic models.
  • Metastasis and regional control progression: For lung metastasis, lymph node metastasis, pelvic dissemination, or peritoneal implantation, use metastasis models or extend orthotopic model observation. Do not rely solely on subcutaneous tumor volume at this stage.
  • Immune confirmation stage: For HPV antigen immunity, therapeutic vaccines, PD-1/PD-L1, STING, cytokines, or radiotherapy combination, prioritize TC-1 syngeneic immunocompetent models. For human immune effector-dependent drugs, escalate to humanized immune models.
  • Relapse and MRD stage: For post-radiotherapy residual disease, peri-treatment intervention, postoperative relapse, or MRD clearance, use orthotopic models with local treatment followed by follow-up, evaluating relapse, pelvic metastasis, and survival.
  • Cytotoxic agents and conventional chemotherapy: For cisplatin, carboplatin, and taxanes, explore efficacy and dose in subcutaneous CDX, then validate local scenarios in orthotopic or radiotherapy combination models. For concurrent chemoradiotherapy programs, prioritize orthotopic radiotherapy combination studies.
  • Anti-angiogenic agents: Bevacizumab or anti-VEGF-related programs can be screened in subcutaneous CDX; for chemoradiotherapy combination, local hypoxia, or pelvic lesion control, escalate to orthotopic models.
  • ADCs and tissue factor-targeted agents: For ADC programs, confirm target expression first, then screen in CDX. For tisotumab vedotin-related or tissue factor-targeted programs, set safety evaluations for target expression, ADC tissue distribution, apoptosis/necrosis, ocular toxicity, or systemic toxicity. Key validation should escalate to orthotopic models.
  • Immune checkpoint and bispecifics: For PD-1/PD-L1, CTLA-4, cadonilimab-class dual immune checkpoint strategies, or combination immunotherapy, select TC-1 syngeneic or humanized immune models based on immune mechanism. Conventional human CDX cannot fully evaluate immune effects.
  • Therapeutic vaccines and HPV antigen therapy: For HPV E6/E7 therapeutic vaccines, TCR-T, TCE, and cell therapy programs, prioritize TC-1 models for immunocompetent validation, with humanized models or in vitro human T cell killing assays when needed.
  • Local delivery and sustained-release systems: For local gels, nanoparticles, vaginal/cervical local delivery, radiosensitizers, and local high-exposure formulations, prioritize orthotopic or mucosa-related models and evaluate local tissue drug concentration, lesion penetration, and local safety.
  • Rapid tumor shrinkage and dose finding: Prioritize subcutaneous CDX. Key endpoints include TGI, RTV, terminal tumor weight, body weight, PK/PD, and target pathway changes.
  • Local invasion and pelvic extension: Prioritize SiHa-luc or CaSki-luc orthotopic models. Key endpoints include orthotopic burden, parametrial invasion, pelvic pathology, lymph node metastasis, and survival.
  • Radiosensitization: Prioritize orthotopic models or orthotopic + relapse observation designs. Key endpoints include tumor burden, DNA damage, apoptosis, residual disease, time to relapse, and local tissue injury.
  • Lung metastasis and distant dissemination: Consider tail vein lung metastasis or orthotopic spontaneous metastasis models. Key endpoints include lung nodule count, lung weight, BLI/IVIS, lung pathology, and survival.
  • HPV antigen immunity: Prioritize TC-1 syngeneic models. Key endpoints include CD8 T cell infiltration, E6/E7-specific immune response, IFN-γ, Granzyme B, tumor burden, and survival.
  • Relapse and MRD clearance: Prioritize orthotopic models with local treatment followed by relapse observation. Key endpoints include IVIS relapse, local relapse rate, pelvic metastasis, survival, and residual lesion molecular markers.
  • Systemic administration: Oral, intraperitoneal, intravenous, and subcutaneous dosing are suitable for subcutaneous CDX, orthotopic, metastasis, and immune models. Set dosing frequency based on half-life, toxicity window, and model progression rate.
  • Local administration: Local gels, vaginal/cervical dosing, local sustained release, nanodelivery, and local high-exposure formulations are better suited to orthotopic or mucosa-related models. Evaluate local drug concentration, tissue distribution, and mucosal safety in parallel.
  • Radiotherapy combination: For radiotherapy combination programs, define irradiation dose, fractionation, dosing sequence, and observation window. Concurrent cisplatin radiotherapy can serve as a standard reference framework.
  • Combination immunotherapy: Set dosing sequence based on mechanism, such as immunotherapy after radiotherapy induction, checkpoint blockade after vaccine induction, or immune maintenance after local treatment. Sampling time should cover the immune activation window.
  • Conventional drug pathway: Subcutaneous CDX early screening → orthotopic model validation of local scenarios → metastasis model for deeper evaluation → relapse model for reinforcement.
  • ADC pathway: Target expression confirmation → target-positive CDX → orthotopic tissue distribution validation → metastasis or relapse model confirmation.
  • Radiotherapy combination pathway: Orthotopic modeling → radiotherapy/concurrent drug combination → residual disease detection → relapse and regional metastasis follow-up.
  • HPV immunotherapy pathway: TC-1 subcutaneous early screening → TC-1 orthotopic or mucosa-related model validation → humanized model confirmation of human immune effects.

Why Alfa Cytology?

HPV Status & Histological Subtype Modeling
Cervical cancer pathogenesis is overwhelmingly driven by high-risk HPV oncogenes (E6/E7) and distinct histology (squamous cell carcinoma vs. adenocarcinoma). Alfa Cytology designs tailored model pathways addressing viral oncogene expression and driver profiles (PIK3CA, STK11), preventing cross-subtype misinterpretation.

Stratified Cell Line Directory
Model selection determines translational validity for targeted agents, ADCs, and immunotherapies. Alfa Cytology helps clients match robust systems—such as HeLa, SiHa, CaSki, and ME-180—based on HPV type (HPV-16 vs. HPV-18), viral integration status, and target expression.

Orthotopic Cervical & Lymphatic Metastasis Models
Subcutaneous CDX models cannot capture local mucosal invasion or pelvic lymph node dissemination routes. Alfa Cytology helps clients generate high-fidelity evidence through orthotopic cervical wall implantation and locoregional metastatic models.

Target Validation & Integrated Immuno-Oncology Workflows
Programs targeting Tissue Factor (TF), TROP2, PD-1/PD-L1, or HPV-targeted T-cell receptor (TCR) therapies require specific microenvironment mapping. Alfa Cytology configures target status scoring, TIL profiling, and integrated PK/PD workflows.

Alfa Cytology is a global leader in OSCC translational research, delivering integrated animal model solutions that span oral mucosal microenvironment, local invasion, cervical lymph node metastasis, premalignant lesion progression, radiotherapy combination, and immune microenvironment evaluation. If you are interested in our services, please don't hesitate to contact us to learn how we can accelerate your OSCC drug development.

For research use only.

Online Inquiry